
SUPPLEMENTARY INFORMATION: Notice is hereby given that, in a letter dated May 26, 1995, the President declared a major disaster under the authority of the Robert T. Stafford Disaster Relief and Emergency Assistance Act (42 U.S.C. 5121 et seq.), as follows:

I have determined that the damage in certain areas of the State of South Dakota, resulting from severe storms, flooding, and ground saturation due to high water tables on March 1, 1995, and continuing, is of sufficient severity and magnitude to warrant a major disaster declaration under the Robert T. Stafford Disaster Relief and Emergency Assistance Act (the Stafford Act). I, therefore, declare that such a major disaster exists in the State of South Dakota.

In order to provide Federal assistance, you are hereby authorized to allocate from funds available for these purposes, such amounts as you find necessary for Federal disaster assistance and administrative expenses. You are authorized to provide Public Assistance in the designated areas. Disaster Unemployment Assistance may be provided at a later date, if warranted. Consistent with the requirement that Federal assistance be supplemental, any Federal funds provided under the Stafford Act for Public Assistance will be limited to 75 percent of the total eligible costs.

The time period prescribed for the implementation of section 310(a), Priority to Certain Applications for Public Facility and Public Housing Assistance, 42 U.S.C. 5153, shall be for a period not to exceed six months after the date of this declaration.

Notice is hereby given that pursuant to the authority vested in the Director of the Federal Emergency Management Agency under Executive Order 12148, I hereby appoint David P. Grier, IV of the Federal Emergency Management Agency to act as the Federal Coordinating Officer for this declared disaster.

I do hereby determine the following areas of the State of South Dakota to have been affected adversely by this declared major disaster:

The counties of Aurora, Beadle, Brookings, Brown, Brule, Buffalo, Butte, Campbell, Charles Mix, Clark, Cocksmiton, Davison, Day, Deuel, Edmunds, Faulk, Gregory, Hamlin, Hand, Hanson, Hughes, Hyde, Jerauld, Jones, Kingsbury, Lawrence, Lyman, McPherson, Marshall, Meade, Pennington, Potter, Roberts, Sanborn, Spink, Stanley, Sully, and Tripp for Public Assistance.

James L. Witt, Director.
[FR Doc. 95–13905 Filed 6–6–95; 8:45 am]
BILLING CODE 6718–02–M

FEDERAL RESERVE SYSTEM
First Citizens Bancorporation of South Carolina, Inc.; Formation of, Acquisition by, or Merger of Bank Holding Companies

The company listed in this notice has applied for the Board’s approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board’s Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that application or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Comments regarding this application must be received not later than July 3, 1995. A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. First Citizens Bancorporation of South Carolina, Inc., Columbia, South Carolina; to merge with SNB Financial Corporation, Summerville, South Carolina, and thereby indirectly acquire Summerville National Bank, Summerville, South Carolina.

Board of Governors of the Federal Reserve System, June 1, 1995.
William W. Wiles, Secretary of the Board.
[FR Doc. 95–13879 Filed 6–6–95; 8:45 am]
BILLING CODE 6210–01–F

FEDERAL TRANSIT ADMINISTRATION
Environmental Impact Statement on the Metro-North Commuter Railroad Dover Plains Branch Improvement Program Between Dover Plains and Wassaic, Dutchess County, NY

AGENCY: Federal Transit Administration (FTA).

ACTION: Notice of Intent.

SUMMARY: The Federal Transit Administration (FTA) and Metro-North Commuter Railroad (Metro-North) intend to prepare an environmental impact statement (EIS), in accordance with the National Environmental Policy Act of 1969, on a proposal by Metro-North to extend commuter railroad service for approximately 5 miles on the Dover Plains Branch of the Harlem Line from the Village of Dover Plains to the Hamlet of Wassaic in the Town of Amenia, Dutchess County, New York.

Stewart Associates; Change in Bank Control Notice

Acquisition of Shares of Banks or Bank Holding Companies

The notificant listed below has applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than June 21, 1995.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:


Board of Governors of the Federal Reserve System, June 1, 1995.
William W. Wiles, Secretary of the Board.
[FR Doc. 95–13879 Filed 6–6–95; 8:45 am]
BILLING CODE 6210–01–F
The Proposed Action, also known as the Wassaic Extension Project, will extend north on the former Penn Central owned right-of-way from the existing Dover Plains Station, pass immediately to the west of the Wassaic Developmental Center (WDC) paralleling NYS Route 22/343, pass through the hamlet of Wassaic, and terminate approximately 3,200 feet (0.6 mile) north of the hamlet adjacent to NYS Route 22/343. The action also includes the construction of a rail yard, station, and 250 parking spaces (150 paved, 100 unpaved) to be located on a site along the alignment just north of Wassaic at the terminus of the proposed extension. A smaller passenger station will be constructed at the WDC with a parking lot of 50 spaces. The total length of the extension project is 5 miles.

The proposed project is intended to help relieve an existing congested parking situation at Dover Plains station, increase the operating efficiency of Metro-North and expand Metro-North's market.

In addition to the Proposed Action, the EIS will evaluate a No-Build alternative and two (2) Build alternatives, as well as any additional alternative(s) generated through the scoping process.

Scoping will be accomplished through correspondence with interested persons and organizations, as well as with federal, state, and local agencies. One (1) public scoping meeting will be conducted.

COMMENT DUE DATE: Written comments on the scope of alternatives and impacts should be submitted by July 20 to Ms. Janet Mainiero, Metro-North Commuter Railroad, 347 Madison Avenue, New York City, New York 10017. Verbal comments should be made at the scoping meeting scheduled below. Verbal comments made at the scoping meeting will be transcribed. Assistance will be provided for the hearing impaired.

SCOPING MEETING: The public scoping meeting concerning the proposed Wassaic Extension Project will be held on: June 20, 1995, 7:00 p.m., Town Hall, Amenia, New York.


SUPPLEMENTARY INFORMATION: FTA and Metro-North Commuter Railroad invite all interested individuals and organizations, as well as federal, state, and local agencies, to participate in identifying the alternatives to be evaluated in the EIS and identifying any significant social, economic, and environmental issues related to the Proposed Action and Alternatives described below. During the scoping process, comments should focus on identifying specific social, economic, and/or environmental issues to be evaluated and suggesting alternatives which may be less costly or less environmentally damaging, while achieving similar transportation objectives. Scoping is not the appropriate forum in which to indicate preference for a particular alternative. Comments on preferences should be communicated after the draft EIS has been completed and issued for review and comment. If you wish to be placed on the mailing list to receive further information as the project develops, contact Ms. Mainiero as described above. Following the public scoping meeting a scoping document will be prepared that will contain the transcript from the public scoping meeting, any written comments received, an outline of the decisions that have been made during the scoping process, and a summary of the issues to be evaluated in a draft EIS.

Description of the Study Area and Project Need

The corridor is approximately 5 miles long, stretching between the village of Dover Plains and the hamlet of Wassaic, in the Town of Amenia, Dutchess County, New York. It is oriented on a north-south axis. The proposed project is intended to provide service to people residing beyond the current Dover Plains terminus, expand Metro-North's market, help relieve an existing congested parking situation at the Dover Plains station, provide more frequent service to the area, and improve the quality of life in the region by implementing a transit project which conforms to the intent of the Clean Air Act Amendments (CAAA) of 1990. In addition, the proposed rail yard will allow Metro-North to increase the efficiency of its operation.

Previous Activity

Metro-North has performed some preliminary analysis on the feasibility of extending the Dover Plains Branch service. Meetings were held with locally elected officials regarding this work. Furthermore, the project has been discussed at public meetings conducted by the Poughkeepsie-Dutchess County Metropolitan Planning Organization (MPO) in 1993 and 1994.

Alternatives

The alternatives proposed for evaluation include:

(1) No Build—This alternative involves no change to transportation services or facilities in the corridor.

(2) The Proposed Action—The Proposed Action involves a 5-mile extension of the Dover Plains Branch on the Harlem Line to a point approximately 2,000 feet (0.4 mile) north of the hamlet of Wassaic where a rail yard, passenger station, and a parking lot consisting of approximately 250 spaces will be constructed. In addition, a small passenger station will also be constructed at the WDC with a parking lot of 50 spaces.

(3) Alternative 1—Alternative 1 includes all the elements of the Proposed Action, except for one passenger station and parking lot. The passenger station and approximately 250-space parking lot will be constructed within the hamlet of Wassaic.

(4) Alternative 2—Alternative 2 involves the extension of the Dover Plains Branch on the Harlem Line to a point approximately 2,000 feet (0.4 mile) north of the existing terminus of Dover Plains. A rail yard and a 250-space parking lot will be constructed in an agricultural parcel immediately north of the Tenmile River. The parking lot will serve the existing station at Dover Plains.

In addition to the construction discussed above, the Build Alternatives will also require track replacement, bridge rehabilitation, and other improvements to bring the existing rail line up to operational standards. The extent of this work is dependent upon the distance of track required for each alternative.

The proposed project and alternatives are based upon the initial technical work performed to date and consultations with local and state officials.

Since the proposed action is preliminary, consideration will be given to modifications to it and the existing alternatives, as well as additional reasonable alternatives. Regard also would be provided to any relevant concerns.

Probable Effects

In the EIS, FTA/Metro-North will evaluate all significant social, economic, and environmental effects, or impacts, of the alternatives. Environmental and social impacts proposed for analysis include water quality, wetlands, cultural resources, community facilities, and traffic and parking impacts near
stations. Impacts on land use, aesthetics, hazardous waste sites, and noise and vibration will also be addressed. The impacts will be evaluated for the construction period and for the long-term period of operation. Measures to mitigate any significant adverse impacts will be considered.

FTA Procedures

The EIS process will be performed in accordance with Federal Transit Laws and FTA’s regulations and guidelines for preparing an Environmental Impact Statement. The impacts of the project will be assessed and, if necessary, the scope of the project will be revised or refined to minimize and mitigate any adverse impacts. After its publication, the draft EIS will be available for public and private agency review and comment. One public hearing will be held. On the basis of the draft EIS and comments received, the project will be revised or further refined as necessary and the final EIS completed.

Issued on June 5, 1995.
Leetitia A. Thompson,
Deputy Regional Administrator.

[FR Doc. 95–13829 Filed 6±6±95; 8:45 am]
BILLING CODE 4910±77±P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Veterinary Medicine Advisory Committee

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Veterinary Medicine Advisory Committee in FDA’s Center for Veterinary Medicine. Nominations will be accepted for vacancies that will or may occur during the next 16 months.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or disabled candidates.

DATES: No cutoff date is established for receipt of nominations.

ADDRESSES: All nominations for membership should be submitted to Gary E. Stefan (address below).

FOR FURTHER INFORMATION CONTACT: Gary E. Stefan, Center for Veterinary Medicine (HFV–244), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1769.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for members to serve on the committee. The function of the committee is to review and evaluate available data concerning safety and effectiveness of marketed and investigational new animal drugs, feeds, and devices for use in the treatment and prevention of animal disease and increased animal production.

Criteria for Members

Persons nominated for membership on the Veterinary Medicine Advisory Committee shall have adequately diversified experience appropriate to the work of the committee in such fields as companion animal medicine, food animal medicine, avian medicine, veterinary pathology, pharmacology, toxicology, pathology, pharmacology, animal science, and chemistry. The specialized training and experience necessary to qualify the nominee as an expert suitable for appointment is subject to review, but may include experience in medical practice, teaching, and/or research relevant to the field of activity of the committee. The term of office is 4 years.

Nomination Procedures

Any interested person may nominate one or more qualified persons for membership on the committee.

Nominations shall state that the nominee is willing to serve as a member of the committee and appears to have no conflict of interest that would preclude committee membership.

FDA will ask the potential candidates to provide detailed information concerning such matters as employment, financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Linda A. Suydam,
Interim Deputy Commissioner for Policy.

[FR Doc. 95–13829 Filed 6–6–95; 8:45 am]
BILLING CODE 4160–01–F

EP Technologies, Inc.; Premarket Approval of EPT±1000 Cardiac Ablation System

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by EP Technologies, Inc., Sunnyvale, CA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the EPT–1000 Cardiac Ablation System. After reviewing the recommendation of the Circulatory System Devices Panel, FDA’s Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of October 28, 1994, of the approval of the application.
ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Mark Massi, Center for Devices and Radiological Health (HFZ–450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–8609.
SUPPLEMENTARY INFORMATION: On September 28, 1992, EP Technologies, Inc., Sunnyvale, CA 94086, submitted to CDRH an application for premarket approval of the EPT–1000 Cardiac Ablation System. The device is a radio frequency-powered cardiac catheter ablation system and is indicated for interruption of accessory atrioventricular (AV) conduction pathways associated with tachycardia, treatment of AV nodal re-entrant tachycardia, and for creation of complete AV block in patients with a rapid ventricular response to an atrial arrhythmia typically chronic, drug refractory atrial fibrillation.

On May 2, 1994, the Circulatory System Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On October 28, 1994, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.
A summary of the safety and effectiveness data on which CDRH based its approval is on file in the

[FR Doc. 95–0121 Filed 6–6–95; 8:45 am]
BILLING CODE 4160–01–F